Physician profile
Gary E Winchester
NPI 1831107176
$719.36
in general payments reported to CMS, 2019-2025
12 companies · $187 in 2025
The $187 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $73.97 · 2023: $241 · 2024: $217 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $645.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $182.70 | 2023-2025 | Vraylar |
| Pfizer INC. | $125.67 | 2022-2025 | |
| Astellas Pharma US INC | $95.67 | 2023-2025 | Myrbetriq, Veozah |
| Dexcom, INC. | $90.89 | 2023-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $61.31 | 2023-2025 | Repatha, Otezla, Otezla |
| Merck Sharp & Dohme LLC | $35.31 | 2022 | |
| Abbott Laboratories | $32.10 | 2024 | Freestyle Libre 3 |
| Corium, LLC | $29.17 | 2023 | Azstarys |
| Novartis Pharmaceuticals Corporation | $18.84 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.91 | 2023 | Eliquis |
| Glaxosmithkline, LLC. | $15.60 | 2023 | Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.19 | 2023 | Xifaxan, Trulance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Winchester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.